Key result
Desethylamiodarone inhibits the oncogenic Kv10.1 channel with ~5 times lower affinity than amiodarone.
Why the study?
Kv10.1 has structure-function properties that are not well understood, prompting the use of clinically important drugs to gain insight into the relationship between pharmacology and its functional properties.
Effect estimate: Kd = 1.1 µM
Desethylamiodarone inhibits the Kv10.1 channel but lacks the hydrophobic interaction required to inhibit the Cole-Moore shift, unlike its parent drug amiodarone.
Does not support changing amiodarone use in patients; leaves open desethylamiodarone as a selective Kv10.1 probe for research.
Kv10.1 is a voltage-dependent K channel whose ectopic expression is associated with several human cancers. Additionally, Kv10.1 has structure-function properties which are not yet well understood. We are using drugs of clinical importance in an attempt to gain insight on the relationship between pharmacology and characteristic functional properties of this channel. Herein, we report the interaction of desethylamiodarone (desAd), the active metabolic product of the antiarrhythmic amiodarone with Kv10.1: desAd binds to both closed and open channels, with most inhibition taking place from the open state, with affinity ~ 5 times smaller than that of amiodarone. Current inhibition by desAd and amiodarone is not synergistic. Upon repolarization desAd becomes trapped in Kv10.1 and thereafter dissociates slowly from closed-and-blocked channels. The addition of the Cole-Moore shift plus desAd open-pore-block time courses yields an increasing phase on the steady-state inhibition curve (H∞) at hyperpolarized holding potentials. In contrast to amiodarone, desAd does not inhibit the Kv10.1 Cole-Moore shift, suggesting that a relevant hydrophobic interaction between amiodarone and Kv10.1 participates in the inhibition of the Cole-Moore shift, which is lost with desAd.
No takes yet. Share an insight, caveat, or question.
Gómez‐Lagunas et al. (2023) studied Kv10.1 channel function (in vitro). Desethylamiodarone vs. Amiodarone or control was evaluated on Kv10.1 channel inhibition (Kd) (Kd = 1.1 µM). Desethylamiodarone inhibits the oncogenic Kv10.1 channel with an apparent affinity of 1.1 µM, approximately 5 times lower than amiodarone, and does not inhibit the Cole-Moore shift.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: